Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18414898 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL18414719 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL1073975 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AGLACSF1R | |
| Water SCHEMBL1662781 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGLACSF1R | |
| SCHEMBL30761569 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL1663200 | 0.72 | CREBBP (0.54) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL1160193 | 0.72 | MEN1 (0.50) | ALDH1A1MEN1KMT2AGLACSF1R | |
| SCHEMBL1185764 | 0.72 | NR3C2 (0.42) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL5788317 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AGLAL3MBTL1 | |
| SCHEMBL276286 | 0.72 | ALDH1A1 (0.60) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3325484-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| EP-2376492-B1 | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-08 | — | — | EP | disclosed |
| US-8981092-B2 | Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1572642-A1 | 3-PYRROLYL UREA DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052852-A1 | 3-PYRROLYL UREA DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| US-6051243-A | USEFUL IN THE TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL CONDITIONS ASSOCIATED WITH A KERATINIZATION DISORDER, DERMATOLOGICAL CONDITIONS (AND THE LIKE) INCLUDING AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-04-18 | — | — | US | disclosed |
| US-5709867-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-20 | — | — | US | disclosed |
| EP-0661260-B1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CIRD GALDERMA (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0661260-A1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | TGFBR2, TGFBR1, SMAD2 | ALDH1A1 2841/4885HPGD 2561/4885MEN1 3092/4885 |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR2, TGFBR1, TGFB2 | ALDH1A1 2746/4885HPGD 2568/4885MEN1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.